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ABSTRACT 26 
Polycomb Repressive Complex 2 (PRC2) maintains repression of cell type-specific genes but 27 
also associates with genes ectopically in cancer. While it is currently unknown how PRC2 is 28 
removed from genes, such knowledge would be useful for the targeted reversal of deleterious 29 
PRC2 recruitment events.  Here, we show that G-tract RNA specifically removes PRC2 from 30 
genes in human and mouse cells. PRC2 preferentially binds G-tracts within nascent pre-mRNAs, 31 
especially within predicted G-quadruplex structures. G-quadruplex RNA evicts the PRC2 32 
catalytic core from the substrate nucleosome. PRC2 transfers from chromatin to RNA upon gene 33 
activation and chromatin-associated G-tract RNA removes PRC2, leading to H3K27me3 34 
depletion from genes. Targeting G-tract RNA to the tumor suppressor gene CDKN2A in 35 
malignant rhabdoid tumor cells reactivates the gene and induces senescence. These data support a 36 
model in which pre-mRNA evicts PRC2 during gene activation and provides the means to 37 
selectively remove PRC2 from specific genes.  38 
 39 
 40 
  41 
 3
Chromatin structure is responsive to changes in transcriptional state but the mechanisms for this 42 
are unclear. Nascent pre-mRNA has primarily been considered to be a passive intermediary but a 43 
potential regulatory role for nascent pre-mRNA may explain some of the changes in chromatin 44 
structure that occur upon gene expression 1. 45 
 46 
The chromatin regulator PRC2 prevents inappropriate activation of genes specific for other cell 47 
types and other stages of cell differentiation 2,3. The PRC2 subunit EZH2 methylates histone H3 48 
lysine 27 (H3K27me3) and, together with PRC1, induces formation of a repressive chromatin 49 
conformation. PRC2 is essential for cell differentiation, both during embryogenesis and 50 
throughout life. Dysregulation of PRC2 function occurs in a range of cancers and can drive 51 
cancer cell proliferation, invasion and metastasis 4. EZH2 methyltransferase inhibitors block 52 
proliferation of a number of cancer cell types, including malignant rhabdoid tumors (MRT), 53 
germinal centre B-cell diffuse large B-cell lymphoma, and diffuse intrinsic pontine glioma 54 
(DIPG) 5-10, and are currently being evaluated in clinical trials. 55 
 56 
The binding of PRC2 to genes is dynamic. During cell differentiation, PRC2 is lost from genes 57 
that become activated and gained at genes that become repressed 11-14. Changes in PRC2 58 
occupancy and H3K27me3 are also observed during cell transformation and in cancer 8,10,15-21. 59 
The oncogenic effects of PRC2 have been linked to ectopic repression of particular genes, for 60 
example CDKN2A (encoding p16INK4A) in MRT and DIPG 5,6,10,22. However, rather than targeting 61 
these key genes specifically, EZH2 inhibition leads to the reactivation of polycomb target genes 62 
across the genome 5,9, which may alter tumor cell identity and promote tumor progression 23. 63 
 64 
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PRC2 is recruited to chromatin through CpG islands (CGIs). Insertion of CGIs into the genome is 65 
sufficient to induce PRC2 recruitment 24-26. The recruitment of PRC2 to CGIs is consistent with 66 
the binding of the accessory factors PHF1 (PCL1) and MTF2 (PCL2) to non-methylated CpG 67 
DNA 27,28 and the binding of JARID2 to H2AK119ub, deposited by PRC1 29,30. Although 68 
recognition of CGIs offers an explanation for the spatial pattern in which PRC2 is associated with 69 
the genome, this mechanism does not account for changes in PRC2 occupancy that occur during 70 
cell differentiation or during cell transformation. Knowledge of the mechanisms responsible for 71 
these dynamic patterns of PRC2 chromatin binding is necessary to understand how cell 72 
differentiation programs are regulated and may allow the development of methods to inhibit 73 
polycomb activity at specific genes. 74 
 75 
In addition to interacting with chromatin, PRC2 also binds RNA but the impact of this on PRC2 76 
function remains unclear. Although first identified to bind specific non-coding RNAs (ncRNAs), 77 
UV-crosslinking-based methods have revealed that PRC2 directly interacts with the majority of 78 
nascent pre-mRNAs and nascent ncRNAs in embryonic stem cells (ESC) 31,32. When binding 79 
short RNA oligonucleotides in vitro, recombinant forms of PRC2 display a preference for 80 
repeated G-tracts, especially when folded into G-quadruplex (G4) structures 33-36, but the 81 
relevance of this for PRC2 RNA function in cells is unknown. First postulated to promote the 82 
recruitment of PRC2 to chromatin, it has recently been found that RNA blocks the interaction of 83 
PRC2 with nucleosomes 31,36 and inhibits its methyltransferase activity 33,37-39. Potentially 84 
consistent with this, global inhibition of RNA polymerase II 40 or global RNA degradation 31 85 
triggers PRC2 recruitment to chromatin at active genes in cells. Similarly, insertion of premature 86 
poly(A) signals 33 or promoter or enhancer inactivation 24,41 increases PRC2 binding and 87 
H3K27me3 in cis. However, whether these results reflect loss of antagonistic RNA, loss of RNA 88 
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polymerase II, or depletion of antagonizing chromatin modifications such as H3K4me3, is 89 
unknown. 90 
 91 
We hypothesized that nascent RNA plays a role in the temporal regulation of PRC2 occupancy at 92 
its target genes. Specifically, we considered that nascent, chromatin-associated RNA may remove 93 
PRC2 from chromatin. To address this, we sought to identify the RNA sequences preferentially 94 
bound by PRC2 in cells and determine the impact of these RNA elements on PRC2 occupancy at 95 
genes. Our results support a model in which chromatin-associated G-tract RNA evicts PRC2 96 
from chromatin during gene activation and provides the means to remove PRC2 from specifically 97 
targeted genes. These data also support the broader consideration of nascent pre-mRNA as a 98 




PRC2 binds G-tracts within nascent RNAs in cells 103 
Using iCLIP, we have previously found that PRC2 directly interacts with the majority of nascent 104 
pre-mRNAs and ncRNAs in mouse ESC 31. We sought to determine whether PRC2 favored any 105 
particular sequence within nascent transcripts. To ensure identified sequences were specific for 106 
PRC2, we also mapped background protein crosslink sites on input RNA. Comparing PRC2 and 107 
input RNA crosslink sites, we identified a strong enrichment of G-tracts at PRC2 RNA binding 108 
sites (Fig. 1a and Supplementary Fig. 1a). Enrichment of these sequences was also observed at 109 
crosslink sites for the RNA binding protein FUS, as has been observed previously in mouse brain 110 
42, but was not apparent for HNRNPC, which binds poly(U) sequences 43. 111 
 112 
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In vitro, the binding of PRC2 to G-tract sequences has been reported to increase when these 113 
RNAs are folded into a G4 structure 35 and we confirmed this to be the case (Supplementary Fig. 114 
1b-d). We therefore explored whether PRC2 maintained this binding preference in cells. 115 
Calculating the propensity for G4 formation across all genes using G4Hunter 44 revealed a peak 116 
in predicted G4 formation 50 nt into the first intron (Fig. 1b). This is consistent with previous 117 
reports of G-tract enrichment at the 5’ end of introns 45,46. Although PRC2 bound these sequences 118 
near the first 5’ splice site, we did not observe any effects of PRC2 on splicing (Supplementary 119 
Fig. 2a).  120 
 121 
To explore whether the potential for G4 formation increased PRC2 RNA binding, we measured 122 
PRC2 crosslink site density at first 5’ splice sites predicted to be able to form G4 structures 123 
versus those that were not. First 5’ splice sites predicted to form G4 structures exhibited 124 
significantly higher PRC2 RNA binding (Fig. 1c and Supplementary Table 1). This increased 125 
binding was localized at the site of predicted G4 formation (Fig. 1d and Supplementary Fig. 2b) 126 
and was observed even when normalizing for G content (Supplementary Fig. 2c). The presence 127 
of a predicted G4 structure was also associated with increased FUS RNA binding at the 128 
beginning of the first intron, consistent with previous reports of FUS binding to G4 RNA in vitro 129 
47, but no change in HNRNPC binding (Fig. 1c). We found that PRC2 bound across the range of 130 
predicted G4 structures but displayed a slight but significant preference for those formed from 131 
smaller numbers of G-tracts (Supplementary Fig. 2d). We conclude that PRC2 preferentially 132 
binds G-tracts within nascent RNAs in cells, especially when predicted to form G4 structures. 133 
 134 
Embedded G4 structures inhibit the interaction of PRC2 with nucleosomes 135 
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PRC2 has been found to exhibit high affinity for short G4-forming RNAs in vitro but whether it 136 
can recognize endogenous G4-forming sequences embedded within longer physiological RNAs is 137 
not clear. Thus, to verify that PRC2 recognizes G4 structures within the context of longer RNA 138 
molecules, we synthesized a previously described 150 nt sequence from the gene PIM1 that 139 
contains a central 23 nt G4-forming sequence, and a control RNA lacking this region (ΔG4) 48 140 
(Supplementary Figs. 3a and b). Examination of iCLIP data showed that PRC2 bound to this 141 
region of PIM1 RNA in mouse ESC (Supplementary Fig. 3c). Incubation of PRC2 with these 142 
RNAs demonstrated that the embedded G4-forming sequence increased RNA binding by 143 
recombinant PRC2 (SUZ12−EZH2−EED−RBBP4 or RBBP7) (Fig. 2a, Supplementary Fig. 3d). 144 
Binding was stronger in buffer containing KCl, which allows G4 formation, compared to buffer 145 
containing LiCl, which does not. Endogenous PRC2 in ESC nuclear extract also bound more 146 
strongly to PIM1 RNA than to ΔG4 RNA or to control RNAs in which the G nucleotides within 147 
the G4-forming sequence were mutated (Fig. 2b).  Then, testing whether PIM1 RNA blocked the 148 
binding of PRC2 to nucleosomes, we found that G4-formation increased the ability of PIM1 149 
RNA to block both recombinant and endogenous PRC2 binding to nucleosomes (Fig. 2c, d and 150 
Supplementary Fig. 3e and f). We conclude that PRC2 recognizes G4 structures embedded within 151 
longer transcripts and this inhibits its interaction with nucleosomes. 152 
 153 
G4 RNA blocks interaction of the PRC2 catalytic core with the substrate core nucleosome 154 
particle 155 
We next sought to explore the basis for the antagonism between RNA and nucleosomes for PRC2 156 
binding. We reasoned that because the PRC2 catalytic core has been reported to be competent for 157 
G4 RNA binding 34, G4 RNA may block the interaction of the PRC2 core with nucleosomes. We 158 
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purified a recombinant catalytic core complex comprising EZH2, EED and the SUZ12 VEFS 159 
domain 49, and, using fluorescence anisotropy, found that it bound to an archetypal G4-forming 160 
RNA ([G4A4]4) and to the endogenous G4-forming sequence within PIM1 RNA in KCl but with 161 
no significant binding in LiCl buffer (Fig. 3a and b).  162 
 163 
In order to measure PRC2 binding to the nucleosome we engineered a nucleosome with a 164 
fluorescently-tagged histone H3 and 147 bp DNA. After confirming that robust binding to 165 
[G4A4]4 and PIM1 G4 RNA was also observed in the low-salt nucleosome binding buffer 166 
required for the fluorescent assay (16.7 ± 1.2 nM and 22.5 ± 1.8 nM, respectively; Supplemental 167 
Fig. 4a and b), we then measured the effect of the RNA on the binding of the catalytic core to 168 
nucleosomes. In the absence of G4 RNA, the PRC2 catalytic core interacted with nucleosomes 169 
with high affinity (25.9 ± 10.7 nM) but in the presence of 500 nM [G4A4]4 RNA, PRC2 binding 170 
to the nucleosome was effectively blocked (Supplementary Fig. 4c). 171 
 172 
The PRC2 catalytic core interacts with the substrate H3 tail through EZH2 and the K27-173 
methylated H3 tail of the allosteric nucleosome through EED. To specifically test the effect of G4 174 
RNA on the binding of the PRC2 catalytic core to its substrate, we used nucleosomes containing 175 
a fluorescently-labeled H3K27M-modified tail, which engages EZH2 but not EED 49,50. In the 176 
absence of RNA, the PRC2 catalytic core interacted with this obligate substrate core nucleosome 177 
particle with high affinity (29.9 ± 3.9 nM). In the presence of [G4A4]4 or PIM1 G4 RNA the 178 
interaction was blocked, whereas a non-G4-forming portion of PIM1 RNA had no effect (Fig. 3c, 179 
d and Supplementary Fig. 4d). Given this antagonistic effect of G4 RNA on the interaction of the 180 
PRC2 core with its substrate, we considered that the RNA may also be able to displace PRC2 181 
from the nucleosome. Strikingly, we found that both [G4A4]4 and PIM1 G4 RNA, but neither 182 
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control non-G4 PIM1 RNA nor poly(A) RNA, was also able to remove PRC2 from a pre-formed 183 
core-PRC2:substrate nucleosome complex (Fig. 3e and f). 184 
To validate these findings, we measured the effect of RNA degradation on the binding of 185 
endogenous PRC2 in nuclear extract to wild-type mononucleosomes either lacking linker DNA 186 
(reconstituted with 147 bp DNA) or containing linker DNA (reconstituted with 183 bp DNA). 187 
We found that RNA depletion increased PRC2 binding to nucleosomes independently of linker 188 
DNA and independently of the DNA-binding accessory factors PCL2, AEBP2 and JARID2 (Fig. 189 
3g and Supplementary Fig. 4e and f). Together, these data show that G4 RNA evicts PRC2 from 190 
the substrate core nucleosome particle via interactions with the PRC2 catalytic core 191 
independently of accessory factors. 192 
 193 
Chromatin-associated G-tract RNA removes PRC2 from genes 194 
The binding of PRC2 to G-tracts within nascent pre-mRNA in cells and the ability of G4 RNA to 195 
evict PRC2 from nucleosomes suggested that G-tracts within nascent RNAs remove PRC2 from 196 
chromatin at genes. We considered that if this hypothesis was correct then mimicking chromatin-197 
associated, nascent RNA by tethering G-tract RNA to the 5’-end of genes with dCas9 should 198 
remove PRC2 from chromatin (Fig. 4a). To test this, we generated a doxycycline (dox)-inducible 199 
HA-dCas9 NIH-3T3 cell line and co-expressed short guide RNAs (sgRNAs) to recruit dCas9 to 200 
the first intron of the PRC2 target gene Fgf11 (Fig. 4b and Supplementary Fig. 5a and b). We 201 
appended to the 3’-end of the sgRNA 51-53 either a 220 nt sequence composed of repeated G-202 
tracts, an equal length sequence with the same overall G-content (50%) but lacking sequential 203 
runs of Gs, or a control RNA in which the G-tracts were replaced with A-tracts, which PRC2 204 
binds only weakly in vitro 33,35 and which are depleted from PRC2 binding sites in cells (Fig. 1a 205 
and Supplementary Fig. 1a). We then performed ChIP for HA-dCas9, SUZ12, H3K27me3, total 206 
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H3 and non-specific IgG control, before and after induction of dCas9 (Fig. 4b and Supplementary 207 
Fig. 5c). As predicted, dCas9 induction led to specific recruitment of the dCas9-G-tract-RNA, 208 
dCas9-G-rich-RNA, and the dCas9-A-tract-RNA ribonucleoproteins to Fgf11. dCas9-tethered G-209 
tract RNA significantly reduced PRC2 binding and H3K27me3 at Fgf11 but not at other genes. 210 
No change was observed in total histone H3 occupancy. In contrast, dCas9-tethered G-rich or A-211 
tract RNAs had no effect on PRC2 chromatin binding or H3K27me3. The loss of PRC2 212 
occupancy was not caused indirectly by induction of Fgf11 transcription (Supplementary Fig. 213 
5d). We conclude that chromatin-associated G-tract RNA is sufficient to remove PRC2 and 214 
deplete H3K27me3 from genes.  215 
 216 
We sought to determine whether the effect of chromatin-associated G-tract RNA was specific to 217 
PRC2. No changes were observed in the levels of H3K27ac or H2AK119ub (Fig. 4c and 218 
Supplementary Fig. 5e), demonstrating that loss of PRC2 was not simply due to occlusion of 219 
chromatin modifying enzymes by G-tract RNA.  We also examined whether proximity to the 220 
PRC2 binding site on chromatin was important for the effect of chromatin-associated G-tract 221 
RNA. Tethering G-tract RNA to a non-PRC2-bound site at the 3’ end of Fgf11, 2.25 kb from the 222 
PRC2-bound CGI at the 5’ end of the gene, had no effect on PRC2 or H3K27me3 occupancy at 223 
the CGI, suggesting proximity of the RNA to the site of PRC2 binding on chromatin is important 224 
for PRC2 removal (Supplementary Fig. 5f). 225 
 226 
We next asked whether the continued presence of a G-tract RNA was required to prevent PRC2 227 
recruitment to its target genes. We removed dox from the cells, causing loss of dCas9 expression 228 
(Supplementary Fig. 5a), and repeated the measurements of PRC2 occupancy and H3K27me3. 229 
We found that dox removal led to a partial restoration of PRC2 chromatin binding and full 230 
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restoration of H3K27me3 (Fig. 4d and Supplementary Fig. 5g). We conclude that while it is 231 
present, chromatin-associated G-tract RNA actively prevents PRC2 binding to CGI chromatin 232 
and that loss of the RNA subsequently allows PRC2 recruitment and H3K27me3 at the gene. 233 
 234 
We sought to determine whether endogenous G-tract RNA sequence spanning the first exon-235 
intron junction could also remove PRC2 from genes. As we had found for the artificial G-tract 236 
RNA, tethering RNA sequence from the 5’ end of Fgf11 to the Fgf11 gene resulted in depletion 237 
of PRC2 and loss of H3K27me3 (Fig. 4e). Thus, endogenous G-tracts located around the first 5’ 238 
splice site of nascent RNA can also remove PRC2 from chromatin. 239 
 240 
PRC2 transfers from chromatin to RNA upon gene activation 241 
The transfer of PRC2 from chromatin to chromatin-associated G-tract RNA suggested that PRC2 242 
also transfers from chromatin to nascent pre-mRNA upon gene activation (Fig. 5a). Cell 243 
transformation induced by oncogenic HRasV12 is accompanied by dynamic changes in PRC2 244 
chromatin occupancy 15,16,18,19,41. Notably, expression of HRasV12 leads to activation of Adcy7 and 245 
Sorcs2 and the subsequent loss of PRC2 18. Loss of PRC2 from Sorcs2 is dependent on the 246 
Sorcs2 TSS 41, consistent with a role for the nascent pre-mRNA. Consistent with this hypothesis, 247 
we found that activation of Adcy7 and Sorcs2 downstream of HRasV12 was accompanied by a 248 
change in PRC2 from binding chromatin to binding the pre-mRNA (Fig. 5b,c and Supplementary 249 
Fig. 6a-c).  We next tested whether chromatin-associated G-tract RNA recapitulated the effect of 250 
gene activation on PRC2 binding at these genes. Tethering G-tract RNA, but not A-tract RNA, to 251 
Adcy7 reduced PRC2 binding and H3K27me3 at this gene but had no effect on PRC2 occupancy 252 
at Sorcs2 (Fig. 5d and Supplementary Fig. 6d). Reciprocally, tethering G-tract RNA to Sorcs2 253 
reduced PRC2 occupancy and H3K27me3 at this gene but had no effect on Adcy7 (Fig. 5e and 254 
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Supplementary Fig. 6e). Thus, PRC2 transfers from chromatin to nascent pre-mRNA upon gene 255 
activation and this can be recapitulated by tethering G-tract RNA to genes. 256 
 257 
G-tract RNA reverses ectopic recruitment of PRC2 triggered by oncogenic HRas 258 
Cell transformation mediated by oncogenes such as HRasV12 causes changes in PRC2 association 259 
with chromatin, including ectopic recruitment to specific genes. PRC2 activity can be inhibited in 260 
cancer cells with small molecules but this reactivates PRC2 target genes non-specifically. We 261 
postulated that G-tract RNA tethering would instead allow the specific reversal of deleterious 262 
PRC2 recruitment events (Fig. 6a). HRasV12-mediated recruitment of PRC2 to Smad6 is 263 
necessary for Ras-induced senescence 19 and is dependent on transcriptional repression 41. 264 
Consistent with this dependence on transcription repression reflecting loss of the competing 265 
nascent pre-mRNA, we found that expression of HRasV12 resulted in a switch in PRC2 binding 266 
from nascent pre-mRNA to chromatin at Smad6 (Fig. 6b). We next asked whether chromatin-267 
associated G-tract RNA could reverse this recruitment of PRC2 to chromatin at Smad6 in 268 
HRasV12-expressing cells. We found that tethering G-tract RNA to Smad6 countered HRasV12-269 
mediated PRC2 recruitment and reduced H3K27me3 at the gene (Fig. 6c and Supplementary Fig. 270 
6f). As we had found for the other genes tested, G-tract RNA tethering and the resultant PRC2 271 
loss was not sufficient to activate Smad6 transcription (Supplementary Fig. 6g). We conclude that 272 
G-tract RNA tethering allows the reversal of oncogene-mediated PRC2 recruitment events. 273 
 274 
G-tract RNA tethering activates the tumor suppressor gene CDKN2A in MRT cells 275 
PRC2 silences tumor suppressor genes in a number of cancer types, including CDKN2A 276 
(p16INK4a) in MRT and DIPG 5,6,10,22. We therefore sought to determine the effect of tethering G-277 
tract RNA to this gene in MRT cells. We found that recruitment of G-tract, but not A-tract, RNA 278 
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caused loss of PRC2 and H3K27me3 (Fig. 7a and Supplementary Fig. 7a and b). Strikingly, this 279 
was sufficient to activate CDKN2A and increase p16INK4a protein levels to a similar extent to the 280 
chemotherapeutic agent cisplatin and the EZH2 inhibitor EI1 (Figs. 7b and c). Furthermore, 281 
CDNK2A upregulation was mirrored by an increase in the proportion of senescent cells (Fig. 7d 282 
and Supplementary Fig. 7c). We conclude that G-tract RNA tethering can be used to reverse 283 





Current models of how PRC2 interacts with chromatin provide an explanation for the spatial 289 
distribution of PRC2 within the genome, but they do not account for the changes in PRC2 gene 290 
occupancy that occur during cell differentiation or in cancer. We have discovered that chromatin-291 
associated G-tract RNA removes PRC2 from its target genes. We found that PRC2 directly binds 292 
G-tracts within nascent RNAs, especially those at the first 5’ splice site predicted to form G4 293 
structures. G4 RNA binds to the PRC2 catalytic core and antagonizes its interaction with the 294 
substrate core nucleosome particle. Consistent with this, PRC2 is transferred from chromatin to 295 
nascent pre-mRNA during gene activation and chromatin-associated G-tract RNA is sufficient to 296 
remove PRC2 from chromatin and deplete H3K27me3. These results support a model in which 297 
G-tracts within nascent RNA remove PRC2 from chromatin during activation of polycomb-298 
repressed genes. We also demonstrate that this mechanism can be exploited to allow the targeted 299 
removal of PRC2 from tumor suppressor genes in cancer cells. 300 
 301 
The mechanisms responsible for the removal of PRC2 from chromatin have been unclear. A 302 
number of recent studies have demonstrated that PRC2 recruitment is responsive to the activation 303 
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state of the gene. Inhibition of RNA polymerase II or insertion of premature poly(A) signals 304 
triggers PRC2 recruitment to CGIs at active genes 33,40. Similarly, the removal of PRC2 from 305 
genes during HRasV12-mediated cell transformation is dependent on their transcriptional 306 
activation 41. Furthermore, PRC2 is recruited to CGIs inserted into the genome, but not if they 307 
contain binding sites for transcriptional activators present in the cell 26 or if they are positioned 308 
between an active promoter-enhancer pair 24. These results show that PRC2 is only able to stably 309 
associate with chromatin in the absence of transcriptional activity. Based on experiments 310 
showing that global RNA degradation triggers PRC2 recruitment to transcribed genes and that 311 
RNA inhibits PRC2 nucleosome interaction and methyltransferase activity 31,33,36-39, we and 312 
others have suggested that one of the features of active genes that inhibits PRC2 function is the 313 
nascent pre-mRNA itself. Our results support this model, demonstrating that chromatin-314 
associated RNA can prevent PRC2 recruitment to active genes and, in addition, that G-tract RNA 315 
removes stably-associated PRC2 from genes. 316 
 317 
Our data clarifies the nature of PRC2 RNA binding specificity and provides an explanation as to 318 
its function. PRC2 RNA binding activity was first identified through its association with specific 319 
ncRNAs. Systematic measurement of direct RNA binding in cells later revealed that PRC2 binds 320 
the majority of nascent pre-RNAs and ncRNAs in a promiscuous manner 31, a conclusion also 321 
drawn from lower-stringency native RNA IP experiments 54. Although PRC2 was initially 322 
observed to bind a broad range of RNAs in vitro 54, later studies using more homogenous short 323 
oligonucleotides revealed specificity for repetitive G-tract sequences, especially when folded into 324 
G4 structures 34-36. Potentially consistent with this, it was also reported that G-tract sequences 325 
were enriched in RNAs that co-precipitated with EZH2, but not with SUZ12, from 326 
formaldehyde-crosslinked HeLa cells 35. However, questions remained regarding the discordant 327 
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results between EZH2 and SUZ12, whether the detected interactions were direct or indirect, the 328 
inability of the method to distinguish RNA-strandedness, whether G-tract sequences were the 329 
most enriched sequences at PRC2 RNA binding sites, and the locations of these sequences within 330 
RNAs. Our measurements of PRC2 RNA crosslinking in cells at single-nucleotide resolution 331 
reveals that G-tract sequences with the potential to form G4 structures are the preferred RNA 332 
binding sites for PRC2 in cells and that these are predominantly localised just downstream of the 333 
first 5’ splice site. The concentration of these sequences at the 5’ end of nascent RNAs, in close 334 
proximity to the site of PRC2 binding on chromatin, may aid the removal of PRC2 from genes. 335 
However, although PRC2 displays a preference for G-tract RNAs, it can bind other RNA 336 
sequences in vitro and in cells and thus other nascent RNA elements may also be able to remove 337 
PRC2 from chromatin, albeit less efficiently. Additional studies will be required to determine 338 
whether G-tract sequences located near the 5’ end of RNAs are required for the removal of PRC2 339 
from chromatin. Such experiments will need to avoid disrupting the functions of G-tract 340 
sequences in splicing 55,56 and the function of the corresponding DNA sequences as transcription 341 
factor and PRC2 and PRC1 binding sites within CGI promoters.  342 
 343 
PRC2, augmented by the accessory subunits PHF1, MTF2 or PHF19 (in PRC2.1) or JARID2 and 344 
AEBP2 (in PRC2.2), forms multivalent interactions with the nucleosome core, modified histone 345 
tails and DNA 2. Recent structural analysis showed the details of the interaction between the 346 
catalytic EZH2 SET domain and the substrate nucleosome and between EED and the K27-347 
methylated nucleosome 57, whilst the non-catalytic lobe of PRC2 has recently been shown to 348 
cooperate with AEBP2 and JARID2 to form a further nucleosome interaction surface 58. 349 
Consistent with previous results 34,39, we found that the minimal catalytically active PRC2 core 350 
(EZH2, EED and the SUZ12 VEFS domain) binds RNA and does so preferentially in conditions 351 
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favoring G4 formation. We therefore focused on potential antagonism between G4 RNA and the 352 
substrate core nucleosome particle for binding to the PRC2 catalytic core. Using a well-defined 353 
system consisting of the PRC2 catalytic core and an obligate substrate nucleosome reconstituted 354 
with 147 bp DNA, we found that G4 RNA blocks the binding of the PRC2 catalytic core to the 355 
substrate core nucleosome particle. Significantly, titration of G4 RNA disrupted a preformed 356 
complex of the PRC2 catalytic core and the substrate nucleosome, which is consistent with our 357 
finding that chromatin-associated G-tract RNA evicts PRC2 from chromatin in cells. The 358 
competitive effect of RNA on PRC2 nucleosome binding in nuclear extracts was also unaffected 359 
by the absence of PRC2 accessory factors. These experiments demonstrate that G4 RNA blocks a 360 
fundamental aspect of PRC2 function that is common to both PRC2.1 and PRC2.2. Other PRC2 361 
RNA binding surfaces have been identified in JARID2 36,37,59 and AEBP2 35 in PRC2.2 and RNA 362 
blocks binding of PRC2.2 to histone-free DNA 36 and to non-histone substrates 39. Thus, further 363 
studies will be required to determine whether additional PRC2-chromatin interactions are also 364 
antagonized by G4 RNA in cells. 365 
 366 
Our results show that chromatin-associated G-tract RNA can remove PRC2 from chromatin and 367 
deplete repressive chromatin modification. Other studies have also demonstrated a role for 368 
nascent pre-mRNA in countering the function of negatively-acting chromatin regulators. For 369 
example, nascent pre-mRNA interacts with DNMT1 and RNA blocks DNMT1 activity 60. On the 370 
other hand, nascent pre-mRNA promotes the interaction of positively-acting regulators with 371 
chromatin, including the transcription factor YY1 52 and the histone methyltransferases Set1 and 372 
Set2 61. Unspliced, chromatin-associated RNA has also been found to promote HNRNPU 373 
oligomerisation and chromatin decompaction 62. Together with the data shown here, these studies 374 
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argue that nascent pre-mRNA is not merely a passive intermediary but plays a direct role in 375 
altering chromatin state to promote its own production 1.  376 
 377 
By showing that tethered G-tract RNA removes PRC2 from chromatin, we have discovered a 378 
means to selectively remove PRC2 from specifically targeted genes. PRC2 removal can have no 379 
effect on gene expression (as is the case for Adcy7, Sorcs2 and Smad6) or can induce gene 380 
activation (as is the case for CDKN2A), demonstrating that the requirement for PRC2 in the 381 
maintenance of gene silencing is context-dependent. Unlike small molecule inhibitors of PRC2 382 
activity that block PRC2 function genome-wide, G-tract RNA tethering allows the selective 383 
reversal of deleterious PRC2 recruitment events, which, in the case of CDKN2A, allows gene 384 
activation and the induction of senescence. This ability to reverse PRC2 recruitment at specific 385 
genes may also allow the identification of individual gene silencing events critical for 386 
oncogenesis. Other methods, such as CRISPR activation 63, enable targeted transcriptional 387 
activation of specific genes. However, the ectopic recruitment of activators results in non-388 
physiological levels of expression that are no longer responsive to endogenous regulatory cues. In 389 
contrast, G-tract RNA tethering selectively removes the repressive regulatory layer. Tethering of 390 
G-tract RNA may thus facilitate the physiological re-activation of specific polycomb target genes 391 
that are inappropriately silenced in disease.  392 
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FIGURE LEGENDS 573 
 574 
Fig. 1. PRC2 binds G-tracts with the potential to form G4 structures in nascent RNA.  575 
(a) Enrichment of 8-mer sequences at PRC2, FUS and HNRNPC RNA crosslink sites identified 576 
by iCLIP (vs input controls). Gs per 8-mer are indicated by color. The ten 8-mers with the 577 
highest z-score are labeled. 578 
(b) Average G4 prediction score (G4-forming sequences (G4FS)) for the coding (dark blue, 579 
above x-axis) and non-coding (cyan, below x-axis) strands around mouse gene splice sites.  580 
(c) RNA crosslink density for PRC2, FUS, HNRNPC, and their input controls at the set of first 5’ 581 
splice sites that are predicted (red, n=942) or not predicted (blue, n=760) to be able to form G4 582 
structures (PRC2 P<2.2x10-16, FUS P<2.2x10-16, Wilcoxon rank-sum test). 583 
(d) Left: Heat map (blue) showing the position of sequences predicted to be able to form G4 584 
structures -30 to +300 nt around the first 5’ splice site of nascent RNAs expressed in mouse ESC. 585 
Right: Heat maps (red) showing the position of PRC2 and input RNA crosslink sites at the same 586 
5’ splice sites. The number of crosslink sites per 5 nt window is indicated by color. 587 
 588 
Fig. 2. G4 structures within longer RNAs block PRC2 binding to nucleosomes.  589 
(a) Immunoblot for SUZ12 after pull-down of recombinant PRC2 (EZH2−SUZ12−EED −RBBP4 590 
or RBBP7) with pre-folded biotinylated PIM1 RNA or control PIM1 RNA lacking G4-forming 591 
sequence (ΔG4) in KCl or LiCl-containing buffer. Streptavidin beads were incubated with 500, 592 
50 or 5 ng/ul of RNA, washed, and then incubated with PRC2. Representative of three 593 
independent experiments (others shown in Supplementary Fig. 3d).  594 
(b) Immunoblot for SUZ12, EZH2, JARID2 and ACTB after pull-down of PRC2 from ESC 595 
nuclear extract with 10-fold dilutions of biotinylated wild-type PIM1 RNA, ΔG4 RNA, G-to-H 596 
RNA (G4-forming G nucleotides mutated to non-G) and G-rich RNA (G-to-H RNA with an 597 
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equal number of non-G to G mutations outside of the G4-forming region). Representative of two 598 
independent experiments. 599 
(c) Immunoblot for SUZ12 and H3 after pull-down of recombinant PRC2 with biotinylated 600 
nucleosomes (reconstituted with 185 bp DNA) in the presence of PIM1 or ΔG4 RNA (2, 20 or 601 
200 ng/μl). Representative of three independent experiments (others shown in Supplementary 602 
Fig. 3e). 603 
(d) Immunoblot for SUZ12, EZH2, JARID2, ACTB and H3 after pull-down of PRC2 from ESC 604 
nuclear extract with biotinylated nucleosomes in the presence of biotinylated wild-type PIM1, 605 
ΔG4, G-to-H or G-rich PIM1 RNA (2, 20 or 200 ng/μl). Representative of two independent 606 
experiments. Uncropped blot images are shown in Supplementary Data Set 1. 607 
 608 
 609 
Fig. 3. G4 RNA inhibits interaction of the PRC2 catalytic core with the substrate core 610 
nucleosome particle. 611 
(a) Fluorescence anisotropy measuring binding of the PRC2 catalytic core (EZH2−EED−SUZ12 612 
VEFS domain) directly to fluorescein labelled [G4A4]4 RNA in either 100 mM K+ or Li + buffer 613 
(mean and S.E., n=3 independent experiments). 614 
(b) As (a) except for the 24 nt G4-forming sequence within PIM1 RNA.  615 
(c) Fluorescence intensity measuring binding of the PRC2 catalytic core directly to MDCC-616 
labeled H3K27M obligate substrate core nucleosome particles (reconstituted with 147 bp DNA) 617 
in the presence of 500 nM [G4A4]4 RNA or no RNA (mean and S.E., n=3 independent 618 
experiments). 619 
(d) As (c), except with 500 nM PIM1 G4 RNA or a control non-G4-forming 24 nt portion of 620 
PIM1 RNA. 621 
(e) Titration of [G4A4]4 and control A40 RNAs into a pre-formed complex of core PRC2 and 622 
MDCC-labeled substrate core nucleosome particle. The increase in fluorescence intensity with 623 
[G4A4]4 RNA is interpreted as release of PRC2 from the nucleosome (mean and S.E., n=3 624 
independent experiments). 625 
(f) As (e), except with G4 and non-G4 forming PIM1 RNAs. 626 
(g) Immunoblot for SUZ12, PCL2, HMGN1 and H3 after co-immunoprecipitation of PRC2 from 627 
Pcl2GT/GT or Pcl2WT/WT ESC with nucleosomes containing biotin-tagged histone H2A 628 
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(reconstituted with either 185 bp or 147 bp DNA) from mock or RNaseA-treated nuclear extract. 629 
Representative of 2 independent experiments. Uncropped blot images are shown in 630 
Supplementary Data Set 1. 631 
 632 
Fig. 4. Chromatin-associated G-tract RNA removes PRC2 from specific genes in cells.  633 
(a) Hypothesis: G-tract RNA, tethered to chromatin with dCas9, should compete with CGI 634 
chromatin for PRC2, reducing H3K27me3. The same length RNA that is equally G-rich but 635 
lacking G-tracts or RNA in which the G-tracts are replaced with A-tracts, both of which bind 636 
PRC2 only weakly, should both have no effect. 637 
(b) Top: Position of the Fgf11 sgRNA and primer pairs A and B. Bottom: Change in HA-dCas9, 638 
SUZ12, H3K27me3 and total H3 occupancy at Fgf11 and Pax7 measured by ChIP-qPCR after 639 
dox-mediated induction of HA-dCas9 expression in cells containing the Fgf11 sgRNA, to which 640 
G-tract, G-rich or A-tract RNA is appended (mean and S.D., n=3 independent dox inductions. P-641 
values: Fgf11-A G-tract RNA SUZ12=0.0018, H3K27me3=0.14. Fgf11-B G-tract RNA 642 
SUZ12=0.0052, H3K27me3=0.03.  Fgf11-B G-rich RNA SUZ12=0.03, Welch’s one-tailed t-643 
test). 644 
(c) Change in H2AK119ub, H3K27ac and total H3 at Fgf11 and Pax7 before and after incubation 645 
with dox (mean, S.D., n=3 independent dox inductions, no significant changes, Welch’s one-646 
tailed t-test). 647 
(d) Change in HA-dCas9, SUZ12, H3K27me3 and total H3 occupancy at Fgf11 and Pax7 before 648 
and after dox treatment (day 6) and after subsequent dox washout (day 12) (mean and S.D., n=3 649 
independent dox inductions. P-values: Dox induction Fgf11-A G-tract RNA: SUZ12=0.02, 650 
H3K27me3=0.0066. Fgf11-B G-tract RNA SUZ12=0.046, H3K27me3=0.49. Dox washout 651 
Fgf11-A G-tract RNA: SUZ12=0.041, H3K27me3=0.0094. Fgf11-B G-tract RNA SUZ12=0.052, 652 
H3K27me3=0.091, Welch’s one-tailed t-test).  653 
(e) Top: Fgf11 RNA sequence spanning the first exon-intron junction was appended to Fgf11 654 
sgRNA. Bottom: As (b), except using Fgf11 sgRNA to which the Fgf11 RNA sequence has been 655 
appended (mean and S.D., n=3 independent dox inductions. P-values: Fgf11 A SUZ12=2.9x10-4, 656 
H3K27me3=0.0019. Fgf11 B SUZ12=0.045, H3K27me3=0.026, Welch’s one-tailed t-test).  657 
 658 
Fig. 5. PRC2 transfers from chromatin to nascent pre-mRNA during gene activation. 659 
 25
(a) Hypothesis: Upon activation of polycomb target genes, PRC2 switches from binding 660 
chromatin to binding nascent RNA. 661 
(b) SUZ12, H3K27me3 and total H3 chromatin occupancy (with IgG control) at Adcy7, Sorcs2 662 
and Actb before and after HRasV12 expression (mean and S.D., n=3 independent ChIPs. Adcy7 663 
SUZ12 P=0.0051, H3K27me3 P=2.1x10-4. Sorcs2 SUZ12 P=0.0041, H3K27me3 P=4.9x10-4, 664 
Welch’s one-tailed t-test). 665 
(c) SUZ12 binding to Adcy7, Sorcs2 and Actb nascent pre-mRNA before and after HRasV12 666 
expression, measured by RIP-qPCR with and without UV-crosslinking of cells (mean and S.D., 667 
n=3 independent RIPs. Adcy7 SUZ12 +/-Ras P=0.011, Sorcs2 SUZ12 +/-Ras P=0.0019, Welch’s 668 
one-tailed t-test). 669 
(d) Change in HA-dCas9, SUZ12, H3K27me3 and total H3 occupancy at Adcy7 and Sorcs2 after 670 
dox-mediated induction of HA-dCas9 expression in cells containing sgRNA specific for Adcy7 671 
(mean and S.D., n=3 independent dox inductions. Adcy7 G-tract RNA: SUZ12 P=0.014, 672 
H3K27me3 P=0.024, Welch’s one-tailed t-test).  673 
(e) As (d), except in cells containing sgRNA specific for Sorcs2. Sorcs2 G-tract RNA: SUZ12 674 
P=0.017, H3K27me3 P=2.9x10-4, Welch’s one-tailed t-test).  675 
 676 
Fig. 6. G-tract RNA reverses PRC2 recruitment triggered by oncogenic HRasV12. 677 
(a) Hypothesis: Tethered G-tract RNA can reverse the ectopic recruitment of PRC2 to specific 678 
genes that occurs during cell transformation. 679 
(b) Left: SUZ12 binding to Smad6 nascent pre-mRNA before and after HRasV12 expression, 680 
measured by RIP-qPCR with and without UV-crosslinking of cells (mean and S.D., n=3 681 
independent RIPs. Smad6 SUZ12 +/-Ras P=0.043, Welch’s one-tailed t-test). Right: SUZ12, 682 
H3K27me3 and total H3 chromatin occupancy (with IgG control) at Smad6 before and after 683 
HRasV12 expression (mean and S.D., n=3 independent ChIPs. SUZ12 P=0.036, H3K27me3 684 
P=0.021, Welch’s one-tailed t-test).  685 
(c) Change in HA-dCas9, SUZ12, H3K27me3 and total H3 occupancy at Smad6 and Pax7 after 686 
dox-mediated induction of HA-dCas9 in HRasV12-expressing cells containing sgRNA specific for 687 
Smad6 (mean and S.D., n=3 independent dox inductions. G-tract RNA: SUZ12 P=0.0082, 688 
H3K27me3 P=0.02, Welch’s one-tailed t-test).  689 
 690 
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Fig. 7. G-tract RNA tethering activates CDNK2A and induces cell senescence. 691 
(a) Top: Position of the CDNK2A sgRNA and primer pairs A and B. Bottom: Change in HA-692 
dCas9, SUZ12, H3K27me3 and total H3 occupancy at CDKN2A and EVX2 after dox-mediated 693 
induction of HA-dCas9 in G-401 cells containing sgRNA specific for CDKN2A, to which is 694 
appended G-tract or A-tract RNA (mean and S.D., n=2 independent dox inductions). 695 
(b) Change in CDKN2A mRNA abundance in cells described in (a) with and without treatment 696 
with dox or cisplatin (3.3 μM, 24 hrs) (mean and S.D., n=3 independent experiments. G-tract +/-697 
dox P=0.022, Welch’s one-tailed t-test). 698 
(c) Immunoblot for p16INK4a and ACTB in cells described in (a) with and without treatment with 699 
dox, cisplatin (3.3 μM, 24 hrs) or the EZH2 inhibitor EI1 (10 μM, 6 days). Representative of 700 
three independent experiments. Uncropped blot images are shown in Supplementary Data Set 1. 701 
(d) Proportion of senescent cells (β-galactosidase staining) in cultures treated as in (c) (mean and 702 
S.D., n=3 independent dox inductions or n=2 cisplatin and EI1 treatments. G-tract +/-Dox 703 





Cell culture 709 
E14, Ezhfl/fl, Aebp2WT/WT and Aebp2GT/GT (kind gifts from Neil Brockdorff) and Jarid2GT/GT (gift 710 
from Amanda Fisher) mouse ESCs were maintained on 0.1% gelatin in KO-DMEM, 10% FCS, 711 
5% knockout serum replacement, non-essential amino acids, L-glutamine, 2-mercaptoethanol, 712 
penicillin-streptomycin and 1000 U/ml leukemia inhibitory factor (03-0011-100, Stemgent). 713 
Pcl2GT/GT and Pcl2WT/WT (gifts from Adrian Bracken) were maintained in GMEM with the same 714 
supplements, except with no serum replacement and replacing L-glutamine with GlutaMAX. G-715 
401 cells were acquired from Sigma with certification from the European Collection of 716 
Authenticated Cell Cultures (ECACC) and maintained in McCoy 5A media supplemented with 717 
10% FBS, 2 mM L-glutamine and penicillin/streptomycin. NIH-3T3 cells (gift from Bart 718 
Vanhaesebroeck) were cultured in DMEM, 10% FBS and penicillin-streptomycin. All cell lines 719 
were tested negative for mycoplasma. A NIH-3T3 cell line expressing H-RasV12 was generated 720 
by transfecting pWZL hygro H-Ras V12 (gift from Scott Lowe, Addgene plasmid # 1874 62) with 721 
Fugene HD (Promega) and selection in hygromycin (2 μg/ml). For RNA tethering, cells were 722 
transfected with pHAGE TRE dCas9 (Addgene plasmid # 50915, a gift from Rene Maehr and 723 
Scot Wolfe) and selected with 2 μg/ml G418. The dCas9 cell lines was then transfected as before 724 
with pLKO.1-puro U6 sgRNA constructs and selected with puromycin at 1 μg/ml. dCas9 725 
expression was induced using doxycycline (2 μg/ml) for 6 days (with media changed every 2 726 
days). For washout experiments, fresh media was added on day 6, changed every 2 days, until 727 
day 12. When indicated, cells were treated with cisplatin (Sigma) at 3.3 μM for 24 hours or with 728 
EI1 (Generon) 10 μM for 6 days 729 
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 730 
RNA tethering  731 
Tethered sequences were placed at the 3’-end of the sgRNA sequence (taken from pLKO.1-puro 732 
U6 sgRNA), separated by a spacer. The sequences were synthesized as gBlocks (Integrated DNA 733 
Technologies (IDT)) that also comprised BfuAI-stuffer (taken from pLKO.1-puro U6 sgRNA) 734 
and a Pol III T6 terminator (sequences in Supplementary Table 2). The gBlocks were digested 735 
with AgeI and EcoRI (New England Biolabs) and ligated into pLKO.1-puro U6 sgRNA BfuAI 736 
stuffer (Addgene plasmid #50920, a gift from Rene Maehr and Scot Wolfe 64).  737 
 738 
The single guide RNA (sgRNA) targeting sequence for Sorcs2 was previously described 41. Other 739 
sgRNAs were designed using CHOPCHOPv2 65 (sequences in Supplementary Table 2), 740 
synthesized as oligonucleotides, annealed, and inserted into the vector using the BfuAI site. 741 
 742 
A G-rich sequence with the same G-content as the tethered G-tract sequence, appended to the 743 
Fgf11 sgRNA and a 5’ spacer sequence, was ordered as a gBlock (sequence in Supplementary 744 
Table 2), digested with NdeI and EcoRI and cloned into pLKO.1-puro U6 sgRNA BfuAI stuffer. 745 
 746 
A G-tract RNA sequence spanning the Fgf11 exon-intron junction (chr11:69,801,412-69,801,633 747 
in mm10), appended to the Fgf11 sgRNA and a 5’ spacer sequence, was ordered as a gBlock 748 
(sequence in Supplementary Table 2), digested with NdeI and EcoRI and cloned into pLKO.1-749 
puro U6 sgRNA BfuAI stuffer.  750 
 751 
Input iCLIP 752 
iCLIP data for PRC2 (antibody to SUZ12), FUS and HNRNPC were taken from 31. For input 753 
samples, we adapted the iCLIP protocol 66 to allow measurement of background RNA 754 
crosslinking. 2.5 x 107 Ezh2fl/fl cells per sample were irradiated with 254 nm UV-C light in a 755 
Stratalinker 2400 (Stratagene). We used 0.2 J/cm2 for SUZ12 and 0.15 J/cm2 for FUS and 756 
HNRNPC inputs to match energies used previously for the respective RNPs. Cells were lysed in 757 
50 μl of lysis buffer and treated with RNaseI and Turbo DNase (Thermo Fisher Scientific) 758 
following the standard iCLIP protocol 66. Lysates were mixed with NuPAGE loading buffer plus 759 
reducing agent and resolved on a 4-12% NuPAGE Bis-Tris gel (Invitrogen) in MOPS buffer. 760 
RNPs were transferred to a nitrocellulose membrane (Hybond, GE Healthcare) and washed twice 761 
with 1x PBS, following the standard iCLIP protocol, but without the immunoprecipitation step. 762 
Using the autoradiograph previously used for PRC2, FUS and HNRNPC iCLIPs as a mask, we 763 
extracted from the membrane RNPs at 110-130 kDa for PRC2 input samples, 70-120 kDa for 764 
FUS input samples and 55-110 kDa for HNRNPC input samples. We then treated the membrane 765 
as normal to extract the RNA. The RNA pellet was de-phosphorylated using PNK (New England 766 
Biolabs), purified and ligated to the L3 linker according to the iCLIP protocol. Library 767 
construction was performed as described 31. Libraries were quantified using the KAPA Universal 768 
Library Quantification kit. Single-end 50 bp reads were generated on a HiSeq 2500. 769 
 770 
UV RNA immunoprecipitation (UV-RIP) 771 
2x108 cells per UV-RIP were irradiated with 0.2 J/cm2 of 254 nm UV-C light in a Stratalinker 772 
2400. RIP was performed as described 67 with antibodies to SUZ12 (Cell Signaling #3737), HA-773 
dCas9 (3F10, Roche 11867423001), or non-specific IgG control (Abcam ab46540). Beads were 774 
washed 6x with cold NT2 buffer with 1M urea, pelleted and then incubated in 200 μl PK buffer 775 
(100 mM Tris-HCl pH 7.4, 50 mM NaCl, 10 mM EDTA) with 10 μl proteinase K (Roche 776 
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03115828001) for 20 mins at 1,100 rpm and 37°C. An equal volume of PK buffer containing 7M 777 
urea was added and a second incubation performed. Supernatant was collected and RNA purified 778 
by phenol/cholorform extraction.  779 
 780 
RNA quantification 781 
RNA was purified using TRIsure (Bioline), treated with Turbo DNase (Thermo Fisher Scientific) 782 
for 30 mins at 37°C and reverse transcribed using SuperScript III (Life Technologies) and 783 
random hexamer primers. Specific RNAs were quantified by qPCR (Applied Biosystems) using 784 
QuantiTect SYBR Green PCR Kit (Qiagen) with the primers shown in Supplementary Table 2. 785 
 786 
Chromatin IP (ChIP) 787 
Cells were trypsinised from the plate, washed with PBS and cross-linked with 1% formaldehyde 788 
for 20 mins. ChIP was performed as described 31, except that cells were sonicated for 5 cycles for 789 
NIH-3T3 cells or 4 cycles for G-401 cells (30 s “on”, 30 s “off”) using a Diagenode Picoruptor. 790 
ChIP was performed using antibodies to SUZ12 (Cell Signaling 3737), HA-dCas9 (3F10, Roche 791 
11867423001), H3K27me3 (Abcam ab6002 or ab192985), H3K27ac (ab4729), H2AK119ub 792 
(CST 8240s), total H3 (Abcam #ab1791) or non-specific IgG control (Abcam ab46540). 793 
Enrichment of specific gene sequences was measured relative to input DNA by qPCR (Applied 794 
Biosystems) using QuantiTect SYBR Green PCR Kit (Qiagen) with the primers shown in 795 
Supplementary Table 2. 796 
 797 
 798 
Histone methyltransferase assays 799 
30 nM PRC2 (EZH2−SUZ12−EED−RBBP4 or RBBP7; Active Motif 31387) was incubated in 800 
the presence of 0.8 μM nucleosomes in 20 mM Hepes pH 7.9, 150 mM NaCl/KCl/LiCl, 20% 801 
glycerol 0.05% IGEPAL CA-630, 0.25 mM EDTA 1mM DTT, 320 μM SAM and Complete 802 
protease inhibitor for 30 mins at 25oC.  803 
 804 
RNAs for binding experiments 805 
G4-forming PIM1 and control ΔG4 sequences were taken from 48. Two additional control RNAs, 806 
one for which the Gs within the G4-forming sequence were mutated to non-Gs (G-to-H) and a 807 
second for which the Gs within the G4-forming sequence were mutated to non-Gs and an equal 808 
number of non-G nucleotides outside of the G4-forming sequence were mutated to Gs (G-rich), 809 
were synthesized as gBlocks (IDT, sequences in Supplementary Table 2) and cloned into 810 
pcDNA3.1. Linearized vectors were transcribed using the MAXIscript T7 Transcription Kit 811 
(Thermo Fisher Scientific) and RNA treated with Turbo DNase (Thermo Fisher Scientific). 812 
Biotin-14-CTP (19519016 Life Technologies) was added in a 0.4:1 ratio relative to CTP. RNA 813 
integrity was verified by polyacrylamide gel electrophoresis. G4 structure formation was 814 
confirmed using a reverse transcriptase stalling assay 68. [rG4rA4]5, 5’-biotinylated-[rG4rA4]5, 815 
[rGrA]20 and 5’-biotinylated-[rGrA]20 40-mer RNA oligonucleotides were obtained from IDT. 816 
Native gel electrophoresis to measure formation of secondary structure was performed as 817 
described 35. RNA was folded either as described 35 or in pull-down buffer to confirm 818 
maintenance of RNA structure during PRC2 pull-down assays. Radiolabeled RNA was visualised 819 
using a Typhoon phosphorimager (GE) and ImageQuantTL (GE). 820 
 821 
RNA pull-downs  822 
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Biotinylated RNAs were incubated in pull-down buffer containing 10 mM HEPES pH 7.9, 150 823 
mM KCl or LiCl, 0.25 mM EDTA (pH 8.0), 1 mM DTT, 5% Glycerol, 0.05% IGEPAL CA-630, 824 
33 ng/μl BSA, RNaseOUT (Invitrogen) and Complete protease inhibitor and G4 formation 825 
promoted by heating to 95°C before cooling on ice and incubation at 37°C for 30 mins. 500, 50 826 
or 5 ng/μl folded biotinylated-RNA was bound to MyOne Streptavidin T1 Dynabeads (Thermo 827 
Fisher Scientific) for 1 hr at 4°C, washed, and then incubated with 1.5 ng/μl of recombinant 828 
PRC2 (Active Motif 31387) for 3 hrs at 4oC. Beads were washed 3x with binding buffer and then 829 
resuspended in NuPAGE loading buffer. In vitro transcribed biotinylated PIM1 or PIM1-ΔG4 830 
RNA were folded in pull-down buffer containing NaCl and G4 formation was promoted as 831 
above. RNA was bound to MyOne Streptavidin T1 Dynabeads, added to 0.1 μg/μl ESC nuclear 832 
extract, prepared as described 69, and the pull-down allowed to proceed as above. 833 
 834 
Nucleosome pull-downs 835 
Recombinant human histones were expressed in E. coli and purified as described 69. 836 
Nucleosomes were assembled by salt deposition dialysis using a biotinylated 601 sequence-837 
containing 185 bp DNA fragment, as described 69. 50 nM nucleosomes were incubated with 1.5 838 
ng/μl recombinant PRC2 (Active Motif 31387), 10 μl MyOne Streptavidin T1 Dynabeads 839 
(Thermo scientific) and 200, 20 or 2 ng/μl of pre-folded RNA, in pull-down buffer (10 mM 840 
HEPES pH 7.9, 150 mM LiCl or KCl, 0.25 mM EDTA (pH 8.0), 1 mM DTT, 5% Glycerol, 841 
0.05%, IGEPAL CA-630, 320 μM SAM, 33 ng/μl BSA, and Complete protease inhibitor) for 3 842 
hrs at 4oC. Beads were washed 3x at 4oC in Li+ or K+ pull-down buffer supplemented with 1M 843 
urea. For nucleosome pull-downs using nuclear extract, 50 nM nucleosomes were incubated with 844 
0.2 μg/μl mESC nuclear extract, in nucleosome pull-down buffer containing NaCl instead of KCl 845 
or LiCl.  846 
 847 
When measuring the effect of linker DNA, in order to ensure pull-down of PRC2 binding to 848 
intact nucleosomes and not to any potential free DNA, we used nucleosomes containing 849 
biotinylated H2A (Abcam ab200286) assembled using 147 bp or 185 bp non-biotinylated 601 850 
sequence-containing DNA. Beads were washed twice in pull-down buffer with 1 M NaCl and 851 
then twice in pull-down buffer with 150 mM NaCl. Samples were then resuspended in 1x LDS 852 
buffer (Thermo Fisher), heated, spun-down before resolution by SDS-PAGE. 853 
 854 
Immunoblotting 855 
Immunoblotting was performed for SUZ12 (Santa Cruz sc-46264), EZH2 (CST 3147), JARID2 856 
(CST 13594), AEBP2 (CST 14129), PCL2 (Proteintech 16208-1-AP), p16INK4a  (Santa Cruz sc-857 
56330), ACTB (CST 4967), HMGN1 (Bethyl Laboratories A302-363A), HRAS G12V (D2H12, 858 
CST 14412), H3K27me1 (Abcam 61015) and H3 (Abcam ab1791). Proteins were visualised 859 
using Amersham ECL Western Blotting Detection Reagent (GE) and detected using an 860 
ImageQuantLAS 4000 imager and ImageQuantTL (GE). Contrast and brightness was altered in a 861 
linear fashion equally across the whole image. The main figures present cropped images; 862 
uncropped images are presented in Supplementary Data Set 1. 863 
 864 
Recombinant protein production 865 
PRC2 core complex (EZH2−EED−SUZ12 VEFS domain) was purified as described 49. Yeast 866 
histone octamer containing wild-type H3 or H3 with the K27M mutation was expressed in E. coli 867 
and purified using a two-step method as described 70. To label the octamer, the mutation K18C 868 
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was introduced to histone H3 and the fluorophore (7-Diethylamino-3-((((2-869 
Maleimidyl)ethyl)amino)carbonyl)coumarin (MDCC)) attached mixing 40 μM octamer with 200 870 
μM MDCC under non-reducing conditions for 30 mins in the dark, after which labeled 871 
nucleosomes were purified using a PD10 column (GE Healthcare). The completeness of the 872 
labelling reaction was verified by mass spectrometry. Nucleosomes were reconstituted with 147 873 
bp DNA containing the Widom 601 sequence using standard procedure 71. 874 
 875 
Fluorescence binding experiments 876 
Direct binding between RNA and PRC2 was analysed by fluorescence anisotropy using a 877 
fluorescein-labeled (G4A4)4 RNA 878 
(AAAAAAGGGGAAAAGGGGAAAAGGGGAAAAGGGGAAAAAA) or a 28 nt G4-forming 879 
portion of PIM1 RNA (ATCCCGGGGGUGGGGGGUGGGGGUGGGU). RNA was heated to 880 
95°C in 100 mM KCl or LiCl, cooled on ice and incubated at 37°C. All binding experiments 881 
were performed at 20°C, and fluorescence measured on a Jasco FP-8500 spectrofluorometer with 882 
excitation at 495 nm and emission at 525 nm. PRC2 was titrated into 20 nM labeled RNA in 883 
assay buffer (50 mM Tris-HCl pH 7.5, 0.01 % Brij-35, 400 μM SAM) with either 100 mM KCl 884 
or 100 mM LiCl. Fluorescence anisotropy data were analysed using GraphPad Prism (GraphPad 885 
Software, USA) and DynaFit (BioKin Ltd). 886 
 887 
The binding of PRC2 to nucleosomes were performed using fluorescence intensity titrations 888 
utilising MDCC-labeled nucleosome (excitation 430 nm, emission 476 nm). PRC2 was titrated 889 
into 10 nM labeled nucleosomes in 25 mM Tris-HCl pH 7.5, 40 mM KCl, 0.01 % Brij-35, 10 μM 890 
BSA, and 400 μM SAM. Binding was indicated by a decrease in fluorescence intensity. For the 891 
competition experiment, PRC2 was titrated into labeled nucleosomes in the presence of 500 nM 892 
unlabelled (G4A4)4 RNA, PIM1 G4 RNA (CGGGGGUGGGGGGUGGGGGUGGGU) or a 893 
control non-G4-forming portion of PIM1 RNA (GAGUUCUGCUGAAUGCCGCGAAGAU) 894 
using the buffer conditions detailed above. For the PRC2 eviction experiment, the PRC2-895 
nucleosome complex was pre-formed by mixing 50 nM PRC2 and 10 nM MDCC-labeled 896 
nucleosomes and then a titration performed with either (G4A4)4, A40, PIM1 G4 or PIM1 non-G4-897 
forming control RNA. Binding affinities were determined in DynaFit (BioKin Ltd) by applying a 898 
simple 1:1 binding model. 899 
 900 
Measuring cell senescence  901 
The proportion of senescent cells was measured using the Senescence Assay Kit (Abcam 902 
ab228562). Cells were treated as described above, stained for 2 hours and washed according to 903 
the manufacturer’s instructions. Cells were harvested by trypsinization and signal was measured 904 
using the FL-1 channel on a Fortessa X20 flow cytometer and quantified with FlowJo (BD 905 
Biosciences). 906 
 907 
G4 structure prediction 908 
G4 scores were calculated across the mm9 genome using G4Hunter 44 using a 25 nt sliding 909 
window. Sequences with a G4 score above a threshold of 1.2 were selected and overlapped with 910 
splice sites defined by Ensembl 59. Profile plots represent the fraction of G4 forming sequences 911 
at each position, divided by the total number of junctions covering the position. The G4 score 912 
was smoothened over a 30 nt sliding window using the smth.gaussian function from the smoother 913 
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package in R with smoother.gaussianwindow.alpha=2.3 and plotted with the ggplot2 package in 914 
R.  915 
 916 
iCLIP data analysis 917 
iCLIP data were processed using iCount (https://github.com/tomazc/iCount) as described 31. The 918 
unique molecular identifiers (UMIs) were registered and experimental barcodes removed before 919 
mapping the sequences to mm9 using Bowtie version 0.12.7 (command line: -v 2 -m 1 -a --best --920 
strata) in iCount. Reads indicative of PCR duplicates (reads mapping to the same position with 921 
the same UMI) and reads aligning to multiple positions were removed. Crosslinks overlapping a 922 
RepeatMasker feature or ncRNAs under 200 nt in length or annotated as a snoRNA were also 923 
removed 31. High-confidence crosslink sites were identified using the peaks function in iCount 924 
(FDR<0.05), using the RegionsAsOne setting and with a 50 nt flank 43. These were then used as 925 
input into the iCount k-mers function. The frequencies of all possible 8-mers were calculated for 926 
a -30 to +30 nt region around each crosslink site. Enrichment of each k-mer was calculated in 927 
iCount as the actual frequency (ftrue) relative to the average frequency in a set of 100 random 928 
permutations (frandom_avg) and expressed as a z-score z=(ftrue–frandom_avg)/σrandom 
42. The enrichment 929 
of G-rich sequences was also observed if the 20 nt region around the crosslink site was masked 930 
(and thus was not an artifact of crosslinking).  931 
 932 
Crosslink sites were assigned to the nearest splice site junction by iCount (Ensembl59 933 
annotation). First exon-intron junctions were defined as those both annotated by Ensembl59 and 934 
from the de novo transcript assembly obtained from mouse ESC total RNA-seq data 935 
(GSM1632634, GSM16326345, GSM16326346) 31 using Cufflinks and Cuffmerge 72. First exon-936 
intron junctions with a predicted G4-forming RNA structure (G4Hunter 1.75 threshold) within -937 
30 to +300 nt around the first 5´ splice site were identified (942 junctions). Junctions were 938 
classified as non-G4 forming if no G4 structures were predicted by G4Hunter above a threshold 939 
of 1 and there were no G4 regular expression matches ((G[2,20] N[1,7])4-20) -300 to +300 nt around 940 
the splice site (760 junctions). The number of crosslink sites at each position were normalized by 941 
the total number of exons or introns at that position and by the total number of crosslink sites in 942 
the dataset multiplied by 10^9. The data points were smoothened over a 30 nt sliding window as 943 
above. To normalise the crosslink density for G content, the G frequency at each position was 944 
calculated for both groups, and the crosslink density for the non-G4 group divided by the non-945 
G4/G4 G-frequency ratio. The number of crosslink sites per 5 nt window was displayed using the 946 
heatmap.2 function from the gplots package in R.  947 
 948 
Characteristics of G4-forming sequences 949 
The number of G-tracts in each sequence, the number of Gs within each G-tract, the number of 950 
nucleotides in the loops, the base composition within the loops, and the position of the 951 
crosslinked Gs within G-tracts, were calculated using custom scripts and plotted in R. The 952 
expression level of the genes (RPKM) in each group was obtained from total RNA-seq data 31 953 
and log10 transformed.  954 
 955 
Alternative splicing 956 
RNA-seq data from 40 (WT ESC: GSM1399452, GSM1399453, GSM1399454 and SUZ12-/- 957 
ESC: GSM1399458, GSM1399459, GSM1399460) were filtered to remove adapters and low-958 
quality bases as before. Reads were then trimmed to a uniform length of 40 nt and aligned to 959 
mm9 using TopHat2 73 with default parameters. Insert size mean and SD were calculated using 960 
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Picard. Splicing events were defined using MISO 74 (http://genes.mit.edu/burgelab/miso/). 961 
Alternative splicing events were filtered using the following thresholds: num-inc 1 --num-exc 1 --962 
num-sum-inc-exc 10 --delta-psi 0.20 --bayes-factor 2. For comparison, the number of alternative 963 
splicing events that occur during differentiation of ESC to neural precursor cells was calculated 964 
using MISO with the same thresholds using data from 75 ESC: GSM1180294 & GSM1180295; 965 
NPC day 3: GSM1184609 & GSM1184610). 966 
 967 
Statistical analysis  968 
The significance of the increase in the crosslink site density across the set of G4-forming first 969 
exon-intron junctions (n=942) versus the set of non-G4-forming first exon-intron junctions 970 
(n=760) was estimated using a Wilcoxon rank-sum test. The significance of the decrease in the 971 
number of G-tracts per crosslinked, predicted G4 versus non-crosslinked, predicted G4 was 972 
estimated using a Wilcoxon rank-sum test. Measurements of PRC2 RNA or nucleosome binding 973 
were performed in triplicate and data plotted in GraphPad Prism (GraphPad Software, USA) with 974 
error bars representing the standard error of the mean. The significance of changes in HA-dCas9, 975 
SUZ12, H3K27me3, H3K27ac and H2AK119ub occupancy after addition of dox relative to 976 
untreated cells was estimated using an unpaired one-tailed Welch’s t-test (n=3 independent dox 977 
treatments and ChIP experiments).  The significance of changes in HA-dCas9, SUZ12 and 978 
H3K27me3 occupancy after washout of dox relative to dox-treated cells was estimated using an 979 
unpaired one-tailed Welch’s t-test (n=3 independent treatments and ChIP experiments). The 980 
significance of changes in SUZ12 and H3K27me3 occupancy of genes in Ras-expressing NIH-981 
3T3 cells versus parental cells was estimated using an unpaired one-tailed Welch’s t-test (n=3 982 
independent ChIPs). The significance of changes in SUZ12 binding to RNA in Ras-expressing 983 
NIH-3T3 cells versus parental cells was estimated using an unpaired one-tailed Welch’s t-test 984 
(n=3 independent UV-RIPs). The significance of the difference in gene expression between Ras-985 
expressing NIH-3T3 cells versus parental cells and for G-401 cells treated with dox or with 986 
cisplatin was estimated using a one-tailed paired Student’s t-test (n=3 independent RNA 987 
purifications). The significance of the difference in the proportion of senescent cells with and 988 
without treatment with dox, cisplatin or EI1 was estimated using a one-tailed paired Student’s t-989 
test (n=3 independent treatments). A confidence interval of 95% was used to assess significance. 990 
A normal distribution was assumed for all populations subjected to t-tests. Supplementary Data 991 
Set 2 contains t-statistics, confidence intervals, effect sizes, degrees of freedom and p-values for 992 
all t-tests. 993 
 994 
REPORTING SUMMARY STATEMENT 995 
Further information on experimental design is available in the Nature Research Reporting 996 
Summary linked to this article. 997 
 998 
DATA AVAILABILITY 999 
Input iCLIP sequencing data have been deposited in the Gene Expression Omnibus (GEO) with 1000 
accession code GSE120696. Previously published iCLIP sequencing data and RNA-seq data are 1001 
available in GEO under accession code GSE66829. The positions of predicted G-quadruplex 1002 
RNA structures and the positions of PRC2 crosslink sites around first 5' splice sites are provided 1003 
in Supplementary Table 1. Supplementary Data Set 2 contains t-statistics, confidence intervals, 1004 
effect sizes and degrees of freedom for all significance tests. Raw quantitative PCR data and all 1005 
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